FDA approves OTC switch for Differin in the US

12 July 2016 - Deborah Wilkes

Archived

The US Food and Drug Administration (FDA) has approved the switch of Galderma's Differin Gel (0.1% adapalene) from prescription to OTC status. Galderma said adapalene was the "first new active ingredient approved to treat acne without a prescription in over 30 years".

Click tags below for more information on topics:

Nestlé Galderma FDA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: